Associations Between Proinflammatory Cytokines, Laboratory-evoked Pain, and Opioid Response Profiles in Healthy Human Subjects
William Davis,Ami Mange,Nicole Brown,Yi Xie,Emma Patillo,Jennifer Ellis,Kelly Dunn
DOI: https://doi.org/10.1124/jpet.514.965260
2024-05-15
Journal of Pharmacology and Experimental Therapeutics
Abstract:ID 96526 Poster Board 514 Proinflammatory cytokines are recognized as key mediators in the initiation as well as persistence of pain via a variety of proposed mechanisms, such as direct activation of nociceptors, and peripheral and central sensitization of pain. However, little is known regarding how the role cytokines play in the acute pain response in the setting of opioid medications. This study examines associations between cytokine levels and laboratory-evoked pain, as well as subjective response to the prototypic opioid hydromorphone (versus placebo) in healthy human subjects. This was a double-blind, randomized, placebo-controlled within-subject comparison of the prototypical opioid hydromorphone vs placebo in healthy and opioid naïve men (N = 50) and women (N = 50). Participants completed quantitative sensory testing (QST) laboratory-based pain testing prior to admission to a residential research unit and blood samples were collected for cytokine analysis pre and post baseline QST. Participants then received hydromorphone (oral) and placebo using a within-subject design during study days 2-5. Blood samples were analyzed for the proinflammatory cytokines IFN-y, TNF-alpha, the interleukins IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, and the immunoglobulins IgA, IgG, and IgM. Cytokine levels at baseline and post-initial QST, as well as the magnitude of change between pre/post ratings were compared against response during QST and following subsequent hydromorphone dosing[AM1] . Participants were 33.7 (SD = 9.1) years old, 38% Caucasian/White, 46% Black/African American, 5% Asian, and 8% of Hispanic ethnicity. Of the 10 cytokines tested, only baseline levels of IL-6, showed any association with primary outcomes, in addition to the immunoglobulins IgA, IgG, and IgM. The levels of these immunoglobulins at baseline were the most likely to be associated with various QST outcomes. However, neither the values post-QST nor the magnitude of change between baseline and post-QSR were meaningfully or reliably associated with QST response. Regarding the experience of hydromorphone, baseline IL-6 levels were significantly associated with having a more positive experience of hydromorphone as evidenced by greater ratings on positive reports (Drug Effects (r(309) = .15, p < .01), Good Effects (r(309) = .15, p < .01), High (r(309) = .22, p < .01), Like How I Feel (r(309) = .18, p < .01), and Talkative (r(309) = .15, p < .01). IL-6 levels were not associated meaningfully with negative reports (e.g., Bad Effects (p = .71), Nausea (p = .19)). These data suggest that baseline levels of immunoglobulins IgA, IgG and IgM (but not the interleukin cytokines) may be differentially associated with response to laboratory-evoked pain (e.g., QST). However, the magnitude of change in cytokine response was not reliably related to the severity of pain evoked by QST. Data also provide initial evidence that higher baseline levels of IL-6 may confer a more positive experience relative to lower IL-6 levels. More focused research examining the contribution of IL-6 to individual variation in response to opioid medications is warranted. Funding: R01DA035246, R01DA056045, R01DA052937.
pharmacology & pharmacy